James Yao

11PUBLICATIONS
59CO-AUTHORS
Molecular targetsPredictive and prognostic markersInformation systems development methodologies and practiceCancer diagnosisCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Feb 28, 2025
Phase II Trial of Atezolizumab and Bevacizumab for Treatment of HPV-Positive Unresectable or Metastatic Squamous Cell Carcinoma of the Anal Canal.

Van K Morris, Suyu Liu, Kangyu Lin

|Mar 11, 2024
Plasma Growth Hormone as a Prognostic Biomarker to Durvalumab and Tremelimumab in Patients with Advanced Hepatocellular Carcinoma.

Shadi Chamseddine, Michael LaPelusa, Lianchun Xiao

|Feb 08, 2024
Transformation of G1-G2 neuroendocrine tumors to neuroendocrine carcinomas following peptide receptor radionuclide therapy.

Igryl S Cordero-Hernandez, Alicia C Ross, Arvind Dasari

|May 22, 2023
Implementing Innovation: Informatics-Based Technologies to Improve Care Delivery and Clinical Research.

Travis J Osterman, James C Yao, Monika K Krzyzanowska

|Oct 19, 2022
Randomized Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors (ECOG-ACRIN E2211).

Pamela L Kunz, Noah T Graham, Paul J Catalano

|Aug 19, 2022
DLL3 as an Emerging Target for the Treatment of Neuroendocrine Neoplasms.

James Yao, Emily Bergsland, Rahul Aggarwal

Pageof 2

Frequent Collaborators

2 joint publications

Yehia I Mohamed

2 joint publications

Cathy Eng

2 joint publications

Daniel M Halperin

1 joint publications

Mohamed E Abdelsalam